Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MBSelect

Financiado

Cerrado

A novel technology enabling efficient delivery of personalized probiotics to pr...

A novel technology enabling efficient delivery of personalized probiotics to prevent gut related diseases and recover damaged gut microbiota Gut-microbiome is an essential part of human health. Gut bacteria imbalance is now recognized as a crucial factor in the development of many diseases – chronic, obesity, diabetes, liver, cardio, cancer and neurodegenerative. Trad... ver más

30/11/2022

MYBIOTICS PHARMA L...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

MYBIOTICS PHARMA LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 7 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-11-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 69% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

7 Participantes

MYBIOTICS PHARMA LTD

2.00M€ | Lider

DULCES Y CONSERVAS HELIOS

583.92K€ | Participante

GALLETAS GULLON

1.51M€ | Participante

GREFUSA

507.72K€ | Participante

Proyectos interesantes

AB-Prevention

Medical Technol...

Biotechnology

71K€ Cerrado

FibRestoration

Medical Technol...

Biotechnology

150K€ Cerrado

BIO2014-55019-JIN

Medical Technol...

Microbiology

204K€ Cerrado

PROBIÓTICOS PARA LA REGENERACIÓN DE LA DIVERS...

Medical Technol...

Biotechnology

634K€ Cerrado

NOVOBIOME-1

Medical Technol...

Biotechnology

71K€ Cerrado

PTQ-08-03-06248

Medical Technol...

Biotechnology

15K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 30 meses Fecha Inicio: 2020-05-06
Fecha Fin: 2022-11-30

Líder del proyecto

MYBIOTICS PHARMA LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Gut-microbiome is an essential part of human health. Gut bacteria imbalance is now recognized as a crucial factor in the development of many diseases – chronic, obesity, diabetes, liver, cardio, cancer and neurodegenerative. Traditional probiotics used today, aimed at restoring this imbalance, are not effective: They are incapable of delivering sufficient number and variety of bacteria to the correct location in the gut and have them colonize. MyBiotics, a microbiome company, developed a novel technology for very efficient growth, delivery, and colonization of needed bacteria types in the gut. The technology uses innovative fermentation methods to grow complex bacteria communities on micro-particles, dry it to powder and place into capsules administered like any probiotic supplement. MyBiotics proved the technology for single-strain-bacteria and for replicating multi-strain biological samples. In this project it is introducing MBSelect, which will remove the reliance on a biological sample and add formulation of multi-strain communities of human bacteria, grown in pre-selected clusters in any combination. The MBSelect innovation enables, for the first time, the creation of personalized, microbiome-based probiotics, fitted to any purpose – recovery from illness, chronic condition, or as supplements – and fitted to specific microbiome needs of different ethnicities, age, and gender. MyBiotics won and executed a Phase1 feasibility study in 2015, which served as a basis for its development since and for this project application. MyBiotics’ objectives in this project are to complete the development of the MBSelect technology, develop its first three probiotic products, scale them to industrial level, test them, and produce the 1st batch for initial commercial market testing immediately following the project; followed by full EU & US commercialization and scaling. The success of MBSelect is key in realizing the potential of MyBiotics and enabling the company to grow.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores